新城发展控股有限公司 新城控股集团股份有限公司 成功发行 亿美元 高级无抵押债券 发行期限:3年 票面利率:11.8% 定价日期:2026年2月26日 特别鸣谢 · ● 乐居财经 李兰 2月26日，据新城控股官微，新城发展控股有限公司（以下简称"新城发展"）、新城控股集团股份有限公司成功发行3.55亿美 元债。 本次债券为高级无抵押债券，期限为3年，票面利率为11.8%。 本次债券发行的联席全球协调人由花旗集团和海通国际担任。同时，龙石资本担任联席簿记管理人。 公开信息显示，新城发展是一家专注于幸福生活构建的产业投资运营集团，业务涵盖住宅开发、商业开发、商业运营管理以及相关企业股 权投资和资产管理。目前，"新城系"旗下拥有新城控股（601155.SH）、新城发展（01030.HK）和新城悦服务（01755.HK）三家上市公司。 新城控股集团股份有限公司 成功发行 亿美元 高级无抵押债券 发行期限:3年 票面利率:11.8% 定价日期:2026年2月26日 · 特别鸣谢 · 联席全球协调人 信用评级机构 乐居财经 李兰 2月26日，据新城控股官微，新城发展控股有限公司（以下简称"新城发展"）、新城控股集团股份有 ...

【夯实境外融资通道 #新城成功发行3.55亿美元债#】《中国经营报》记者了解到，2月26日，新城控股 （601155.SH）母公司新城发展（01030.HK）宣布，子公司新城环球有限公司成功发行3.55亿美元的优 先担保票据，发行期限3年。 在此背景下，新城作为少数成功发行美元债的民营房企，且接连实现三笔境外债的顺利发行，不仅印证 了国际资本市场对企业经营基本面、抗风险能力及长期发展价值的高度认可，更标志着公司境外融资渠 道持续畅通、融资能力稳步提升，为企业穿越行业周期、实现稳健高质量发展筑牢坚实的资金保障。 中信建投在近期研报中指出，新城控股持有的运营收入稳步提升，多层级REITS战略首单落地，公司向 资产运营深化转型取得了实质性突破，因此预测2025—2027年EPS分别为0.42元、0.52元、0.63元，维持 买入评级和21.82元的目标价不变。#房地产# 中经记者 杨让晨 石英婧 上海报道 信息显示，自2025年6月以来，新城持续打开境外融资渠道，本次美元债的成功发行，进一步夯实了公 司境外资本市场的融资根基。去年6月，新城发展成功发行3亿美元高级无抵押债券，成为近三年来首家 重启境外资本市场融资的 ...

据中指研究院数据统计，2025年房企境外债发行规模仅为161.45亿元人民币，占总融资规模的2.7%，发 行主体以华润、越秀等央国企为主，民营房企境外融资依旧承压。 在此背景下，新城作为少数成功发行美元债的民营房企，且接连实现三笔境外债的顺利发行，不仅印证 了国际资本市场对企业经营基本面、抗风险能力及长期发展价值的高度认可，更标志着公司境外融资渠 道持续畅通、融资能力稳步提升，为企业穿越行业周期、实现稳健高质量发展筑牢坚实的资金保障。 中信建投在近期研报中指出，新城控股持有的运营收入稳步提升，多层级REITS战略首单落地，公司向 资产运营深化转型取得了实质性突破，因此预测2025—2027年EPS分别为0.42元、0.52元、0.63元，维持 买入评级和21.82元的目标价不变。 （文章来源：中国经营报） 《中国经营报》记者了解到，2月26日，新城控股（601155.SH）母公司新城发展（01030.HK）宣布， 子公司新城环球有限公司成功发行3.55亿美元的优先担保票据，发行期限3年。 据悉，此次新城发行债券在花旗集团与海通国际的联席主导下，获得了国际投资者的积极认购，彰显了 资本市场对新城稳健经营及未来发 ...

新华财经北京2月26日电新城控股（601155.SH）母公司新城发展（01030.HK）26日宣布，子公司新城 环球有限公司完成发行3.55亿美元的优先担保票据，发行期限3年。 据了解，此次发行债券在花旗集团与海通国际的联席主导下，获得了国际投资者的积极认购。根据公 告，本次发行所得款项净额将主要用于为同步2026年购买要约提供资金、现有债务再融资及一般企业用 途。 自2025年6月以来，新城持续打开境外融资渠道，本次美元债的发行进一步夯实了该公司境外资本市场 的融资根基。去年6月，新城控股母公司新城发展发行3亿美元高级无抵押债券，成为近三年来首家重启 境外资本市场融资的民营房企；同年9月，在新城控股及新城发展的联合担保下，子公司新城环球再发 行1.6亿美元的优先担保票据，持续巩固境外融资优势。 据中指研究院数据统计，2025年房企海外债发行规模为161.45亿元人民币，占总融资规模的2.7%，发行 主体以华润、越秀等央国企为主。 业内人士表示，新城作为少数完成发行美元债的民营房企，且接连实现三笔境外债的顺利发行，不仅充 分印证了国际资本市场对企业经营基本面、抗风险能力及长期发展价值的高度认可，更标志着境内企 ...

据中指研究院数据统计，2025年房企海外债发行规模仅为161.45亿元人民币，占总融资规模的2.7%，发 行主体以华润、越秀等央国企为主，民营房企境外融资依旧承压。 在此背景下，新城作为少数成功发行美元债的民营房企，且接连实现三笔境外债的顺利发行，不仅充分 印证了国际资本市场对企业经营基本面、抗风险能力及长期发展价值的高度认可，更标志着公司境外融 资渠道持续畅通、融资能力稳步提升，为企业穿越行业周期、实现稳健高质量发展筑牢坚实的资金保 障。 中信建投在近期研报中指出，新城控股持有运营收入稳步提升，多层级REITS战略首单落地，公司向资 产运营深化转型取得了实质性突破。为此，预测2025-2027年公司EPS分别为0.42/0.52/0.63元，维持买入 评级和21.82元的目标价不变。 2月26日，新城控股（601155.SH）母公司新城发展（01030.HK）宣布，子公司新城环球有限公司成功 发行3.55亿美元的优先担保票据，发行期限3年。 此次发行债券在花旗集团与海通国际的联席主导下，获得了国际投资者的积极认购，彰显了资本市场对 新城稳健经营及未来发展的广泛认可。根据公告，本次发行所得款项净额将主要用于为 ...

Group 1 - The overall retail market performance in South China during the 2026 Spring Festival was weak, with a decline in customer traffic and average transaction value being the main factors affecting sales [3] - Consumer travel increased in South China, contributing to the decline in foot traffic in shopping districts [3] - The toy sector remains highly prosperous, with Pop Mart (09992) expected to achieve over 25% growth for the year, driven by strong IP operation capabilities [4] Group 2 - The cosmetics sector showed slight overall growth, but there was a clear divide between foreign and domestic brands, with foreign brands like Dior and MAC recording approximately 10% growth [5] - The restaurant industry exhibited a K-shaped recovery during the Spring Festival, with large dining establishments facing pressure on average transaction values, while fast food and casual dining showed relative stability [6] - The apparel sector's sales remained flat, with growth primarily driven by pre-Festival consumption, and sports brands experiencing a slowdown in same-store sales growth [7] Group 3 - The luggage brand Samsonite (01910) benefited from travel demand, with sales rising approximately 15% year-on-year during January-February 2026 [8] - The jewelry sector saw a decline in customer traffic but benefited from rising gold prices, leading to a high single-digit increase in sales [9]

海通国际发布研报称，2026年春节期间华南百货客流下滑，消费分化明显。潮玩赛道高景气，泡泡玛特 (09992)预计全年增长超25%，毛戈平(01318)凭借核心产品维持高双位数增长。箱包品牌新秀丽(01910) 受益出行需求，1-2月同比回升约15%。餐饮服饰表现平淡，黄金珠宝靠金价支撑销售额。 海通国际主要观点如下： 事件 根据该行近期对某华南百货渠道的调研反馈，该百货渠道2026年春节期间零售市场整体表现平淡，客流 下滑及客单价下降为主要拖累因素 根据专家对多个核心项目的监测，2026年春节假期前六天中有五天商场客流同比录得下跌，仅一天实现 同比增长，整体经营表现低于公司内部预期。尽管车流数据因部分商圈周边停车费用相对较低而普遍上 升，但部分驾车客流可能仅停留于周边项目，并未完全转化为场内实际消费，专家分析指出华南地区消 费者出游人数增多是导致商圈客流同比下降的主要原因之一。 潮玩赛道持续高景气，头部品牌凭借IP运营能力及会员粘性保持强劲增长 根据专家数据，泡泡玛特整体增长强劲，1Q25因Labubu IP爆火同比增长40%左右，同比增速仍保持稳 定，基于其强大的IP运营能力(专家预期26年仍会有一款大热 ...

Core Viewpoint - Haitong International reports that the main business revenue and profit of CSPC Pharmaceutical Group (01093) have bottomed out, with expectations to return to an upward cycle by 2026 and benefit from the launch of innovative oncology and metabolic products starting in 2027 [1] Group 1: Revenue and Profit Outlook - The potential milestone revenue for CSPC Pharmaceutical Group is estimated at $5.8 billion (approximately RMB 40.6 billion), which is expected to gradually enhance the company's profits over the next 3-5 years [1] - The firm believes that upfront payments and milestone revenues will provide sustainable recurring income for the company, leading to an upward revision of the revenue forecast for authorized products post-2027 [1] Group 2: R&D and Collaboration - CSPC Pharmaceutical Group has achieved seven external collaboration deals in the past two years, with total upfront payments of $1.71 billion and potential milestone revenues exceeding $30 billion [2] - The company has partnered with AstraZeneca three times, highlighting its R&D platform's global influence and value [2] - The firm is optimistic about CSPC's ability to generate regular income through milestone sales and net revenue sharing throughout the drug lifecycle [2] Group 3: Pipeline and Technology - CSPC's small nucleic acid platform has a broad layout, targeting popular liver delivery points such as PCSK9, AGT, and ANGPTL3, and is ahead of domestic peers in development [3] - The company has applied for patents related to lipid delivery and specific siRNA treatments, indicating potential advancements in neurological and ocular delivery technologies [3] - The SYS6010 (EGFR-ADC) has accumulated clinical data from over a thousand patients, showing potential for best-in-class efficacy and safety [4] Group 4: Clinical Developments - The company has initiated a Phase III clinical trial for SYS6010 in China for first-line treatment of non-small cell lung cancer (NSCLC) and plans to advance global Phase III trials [4] - CSPC's in vivo CAR-T product, SYS6055, has received clinical approval in China, representing the first in vivo CAR-T product approved domestically, with potential advantages in cost and accessibility [4] Group 5: Financial Projections - The firm has adjusted revenue forecasts for FY25, FY26, and FY27 to RMB 26.7 billion, 28.9 billion, and 30.6 billion respectively, reflecting changes in the recognition of upfront payments [5] - The net profit forecasts for FY25, FY26, and FY27 have been revised to RMB 4.4 billion, 4.6 billion, and 5.3 billion respectively [6]

智通财经APP获悉，海通国际发布研报称，石药集团(01093)的主营业务收入、利润已经触底，2026年有 望回到上升周期，2027年开始受益于肿瘤和代谢创新产品放量，成药收入有望提速。石药集团当前潜在 临床里程碑收入达58亿美元（约人民币406亿元），有望在未来3-5年陆续增厚公司利润。该行认为首付 款和里程碑收入将为公司带来可持续的经常性收益，并上调了2027年后的授权收入预测。该行使用现金 流折现（DCF）模型及FY27-FY35的现金流进行估值。基于WACC 7.9%，永续增长率2.5%（均不 变），对应目标价13.07港元，并维持"优于大市"评级。 海通国际主要观点如下： 研发能力多次获得认可，该行看好常态化里程碑收入夯实公司基本面 近两年来石药集团实现7笔对外合作交易，涉及首付款总额17.1亿美元，潜在里程碑总额超300亿美元。 公司与全球顶尖药企阿斯利康三度达成合作，彰显石药集团研发平台在全球范围的影响力与价值。该行 认为，加总近60亿美元的潜在研发里程碑将会在未来3-5年陆续增厚石药集团的利润，成为公司常态化 收入的重要组成部分。该行看好石药集团可以持续以销售里程碑和销售净额分成的方式在整个药品 ...

Group 1 - The A-share market experienced a positive start to the Year of the Horse, with the Shanghai Composite Index rising by 0.87% and the Shenzhen Component Index increasing by 1.36% on February 24 [2] - The Hang Seng Index fell by 1.82%, and the Hang Seng Tech Index decreased by 2.13% on the same day [2] - As of February 24, there were 8 A+H listed companies experiencing an AH price inversion, where H-share prices exceeded A-share prices, representing approximately 4.6% of the total 174 A+H listed companies [3] Group 2 - The companies with AH price inversion include leading firms across various sectors such as new energy, banking, innovative pharmaceuticals, semiconductors, home appliances, mining, and machinery [4] - The phenomenon of AH price inversion is relatively rare, with no companies experiencing it a year ago on February 24, 2025 [2][4] - The average AH premium rate is typically around 125%, considering the 20% dividend tax on H-shares and the tax exemption for A-shares held for over a year [5] Group 3 - On February 24, the trading volume of A-shares for China Merchants Bank was 75.47 million shares, which is 7.7 times that of its H-shares at 9.8 million shares [5] - The market capitalization of China Merchants Bank is approximately 1.005 trillion yuan, with an AH premium rate of 0.89, indicating an 11% discount of A-shares relative to H-shares [5] - CATL, another leading company, saw its A-shares decline by 0.93% while H-shares fell by 3.13%, with A-share trading volume being 12.5 times that of H-shares [6] Group 4 - The AH premium index closed at 116.99 on February 24, indicating that A-shares are trading at a premium to H-shares, and this index has been on a downward trend since April 9, 2025 [11] - The index has dropped from a high of 144.85 to a low of 113.56, marking an eight-year low [11] - Analysts suggest that the recent trend of foreign capital favoring Hong Kong stocks may be influenced by the appreciation of the yuan, which could lead to a convergence of AH premiums [13] Group 5 - Morgan Stanley highlighted investment opportunities in sectors such as technology and cyclical recovery, particularly in leading companies within these fields [13] - Tianfeng Securities expressed a cautiously optimistic outlook for the Hong Kong market, suggesting a focus on value-oriented investments while maintaining growth as a secondary consideration [13]